abrdn plc Sells 11,574 Shares of Insulet Co. (NASDAQ:PODD)

abrdn plc reduced its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 3.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 305,354 shares of the medical instruments supplier's stock after selling 11,574 shares during the quarter. abrdn plc owned approximately 0.44% of Insulet worth $66,256,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. First Manhattan Co. acquired a new stake in shares of Insulet in the 4th quarter valued at approximately $35,000. Wolff Wiese Magana LLC boosted its holdings in shares of Insulet by 2,680.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier's stock valued at $30,000 after buying an additional 134 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 123 shares during the last quarter. Allworth Financial LP lifted its holdings in Insulet by 104.5% during the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 92 shares during the last quarter. Finally, BluePath Capital Management LLC acquired a new stake in Insulet during the 3rd quarter valued at $31,000.

Insider Buying and Selling

In related news, Director Shacey Petrovic sold 11,609 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.90% of the stock is owned by company insiders.

Insulet Price Performance

Shares of NASDAQ PODD traded up $1.52 during mid-day trading on Friday, reaching $166.25. The company had a trading volume of 844,656 shares, compared to its average volume of 681,912. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. Insulet Co. has a one year low of $125.82 and a one year high of $335.91. The firm has a market cap of $11.64 billion, a price-to-earnings ratio of 57.13, a PEG ratio of 2.99 and a beta of 0.98. The business's 50-day simple moving average is $173.97 and its 200 day simple moving average is $179.15.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The company had revenue of $509.80 million for the quarter, compared to analysts' expectations of $461.26 million. During the same quarter last year, the business earned $0.55 earnings per share. Insulet's revenue was up 37.9% on a year-over-year basis. On average, research analysts predict that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PODD. Barclays cut their price target on Insulet from $214.00 to $213.00 and set an "equal weight" rating for the company in a report on Monday, February 26th. Piper Sandler cut their price target on Insulet from $250.00 to $230.00 and set an "overweight" rating for the company in a report on Friday, February 23rd. Stifel Nicolaus raised their price target on Insulet from $163.00 to $208.00 and gave the company a "hold" rating in a report on Monday, February 5th. Finally, JPMorgan Chase & Co. raised their price target on Insulet from $190.00 to $225.00 and gave the company an "overweight" rating in a report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Insulet presently has a consensus rating of "Moderate Buy" and an average price target of $243.21.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.